Rani Therapeutics Posts $1.7 Million in Q3 Revenue, $0.04 GAAP Loss Per Share

Your call?🐂 Bullish🐻 Bearish

Cash, cash equivalents and marketable securities totaled $45.3 million on Sept. 30, 2026, down from $53.4 million on June 30. Rani expects those funds to cover operations through at least the end of 2027.